Cancer Immunotherapy News and Research

RSS

Better understanding of cell death mechanism could lead to more efficient cancer immunotherapy

Researchers in the group of Prof. Dr. Peter Vandenabeele show that killed tumour cells can serve as a potent vaccine that stimulates the immune system to prevent the outgrowth of cancer cells.

2 Apr 2016

CCCBD offers promising new investigational therapy to treat childhood ALL

The Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles is one of the first sites in the world to offer a promising new investigational therapy to treat pediatric acute lymphoblastic leukemia (ALL).

30 Mar 2016

Microneedle-embedded patch delivers cancer immunotherapy directly to melanoma

Biomedical engineering researchers at North Carolina State University and the University of North Carolina at Chapel Hill have developed a technique that uses a patch embedded with microneedles to deliver cancer immunotherapy treatment directly to the site of melanoma skin cancer. In animal studies, the technique more effectively targeted melanoma than other immunotherapy treatments.

25 Mar 2016

Inhibiting cholesterol esterification can potentiate antitumor activity of killer T cells

As key players in the immune system, T cells provide tumor surveillance and have direct antitumor effects. However, tumors can escape T-cell attack through various mechanisms in the tumor microenvironment. Reactivating the antitumor effects of T cells has shown great clinical benefits in treating various cancers.

18 Mar 2016

STING agonists developed to induce cellular death in B cell malignancies

In almost every mammalian cell, you will find the endoplasmic reticulum, a network of continuous membranes responsible for controlling metabolism as well as the folding, assembly and secretion of proteins.

11 Mar 2016

BioLineRx announces year end 2015 financial results, provides operational update

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2015.

10 Mar 2016

Means to target all tumor cells with one treatment uncovered

Research sponsored by Cancer Research UK has identified mutations common to all tumour cells. Immunotherapies specific for these mutations could deliver chemotherapeutic agents to all tumour cells and destroy them.

4 Mar 2016

Neurosurgeons use laser probe to deliver chemotherapy drugs to patients with glioblastoma

Using a laser probe, neurosurgeons at Washington University School of Medicine in St. Louis have opened the brain's protective cover, enabling them to deliver chemotherapy drugs to patients with a form of deadly brain cancer.

26 Feb 2016

Radiation could increase responses to innovative immune-based therapeutic approaches to fight cancer

A team of Georgia State University researchers is fighting cancers using a combination of therapies and recently found ways that radiation could maximize responses to novel immune-based therapeutic approaches to fight cancer.

1 Feb 2016

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system's potential to fight cancer.

21 Jan 2016

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach.

21 Jan 2016

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments."

21 Jan 2016

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.

19 Jan 2016

Scientists find new way to re-engineer body’s immune system to target cancer

Scientists have demonstrated a new way of re-engineering the body’s immune system to target cancer, paving the way for a new generation of drugs, unprecedented in safety and effectiveness.

18 Jan 2016

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).

5 Jan 2016

UCL Cancer Institute win $200,000 CytoFLEX Flow Cytometer from Beckman Coulter

An internationally renowned gene therapy research team has won a $200,000 CytoFLEX Flow Cytometer from Beckman Coulter Life Sciences.

From Beckman Coulter Life Sciences - Flow Cytometry 18 Dec 2015

Viralytics announces completion of $28 million placement

Viralytics Limited announces that it has completed a placement of 46,118,270 shares to international and domestic sophisticated or professional investors at an issue price of $0.615 per share to raise $28,362,736.

14 Dec 2015

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium, for the phase 3 registrational trial of its cancer immunotherapy ICT-107 in patients with newly diagnosed glioblastoma.

14 Dec 2015

Crucial tumor-suppressing gene protects immune attack against lung cancer

A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

21 Nov 2015

Researchers identify new target for novel immune-oncology treatments

By studying a type of immune cells, a team of researchers at the IRCM led by André Veillette, MD, identified the mechanism of action for a new target for novel immune-oncology treatments. Their discovery is published today in the print edition of the scientific journal the Journal of Experimental Medicine.

17 Nov 2015

Cancer Immunotherapy News and Research

Better understanding of cell death mechanism could lead to more efficient cancer immunotherapy

CCCBD offers promising new investigational therapy to treat childhood ALL

Microneedle-embedded patch delivers cancer immunotherapy directly to melanoma

Inhibiting cholesterol esterification can potentiate antitumor activity of killer T cells

STING agonists developed to induce cellular death in B cell malignancies

BioLineRx announces year end 2015 financial results, provides operational update

Means to target all tumor cells with one treatment uncovered

Neurosurgeons use laser probe to deliver chemotherapy drugs to patients with glioblastoma

Radiation could increase responses to innovative immune-based therapeutic approaches to fight cancer

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Immunotherapy could be the future of cancer treatments

PD-L1 inhibition well-tolerated, active in metastatic RCC

Scientists find new way to re-engineer body’s immune system to target cancer

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

UCL Cancer Institute win $200,000 CytoFLEX Flow Cytometer from Beckman Coulter

Viralytics announces completion of $28 million placement

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

Crucial tumor-suppressing gene protects immune attack against lung cancer

Researchers identify new target for novel immune-oncology treatments

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News